Arrowhead Prices $36 Million Private Offering

News   May 01, 2013

 
Arrowhead Prices $36 Million Private Offering
 
 
 

RELATED ARTICLES

New Strategy for Multiple Myeloma Immunotherapy

News

Osaka University study unveils new target for monoclonal antibody-based treatment of cancer.

READ MORE

Sphere Fluidics and Geneva Biotech Receive Eurostars Genome Editing Grant

News

€1.6 million grant will support ‘precise docking of very large DNA cargoes in genomes’ project.

READ MORE

Meningococcal Vaccine Could Protect Against 91% of Targeted Bacterial Strains

News

“We are very pleased to see that it looks like the vaccine has the potential to cover most of the strains of meningococcal Group B bacteria currently circulating in the U.S.,” said lead study author Gowrisankar Rajam, Ph.D.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE